Diffuse Diabetic Macular Edema Clinical Trial
| NCT number | NCT00600301 |
| Other study ID # | APEC-OO13 |
| Secondary ID | |
| Status | Withdrawn |
| Phase | Phase 3 |
| First received | |
| Last updated | |
| Start date | January 2008 |
| Est. completion date | January 2008 |
| Verified date | May 2024 |
| Source | Asociación para Evitar la Ceguera en México |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | January 2008 |
| Est. primary completion date | January 2008 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years to 90 Years |
| Eligibility | Inclusion Criteria: - Diffuse diabetic macular edema - Non proliferative diabetic retinopathy - No VPP previa - No previous treament with laser, Triamcinolone acetonide, and Bevacizumab Exclusion Criteria: - Proliferative diabetic retinopathy - Previous pars plana vitrectomy - Previous treatment with diabetic macular edema - Focal macular edema - Macular Ischemia |
| Country | Name | City | State |
|---|---|---|---|
| Mexico | Asociacion Para Evitar la Ceguera en Mexico | Mexico |
| Lead Sponsor | Collaborator |
|---|---|
| Asociación para Evitar la Ceguera en México |
Mexico,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00571142 -
Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
|
Phase 3 | |
| Withdrawn |
NCT00567372 -
POSTERIOR SUB-TENON'S Avastin
|
Phase 4 | |
| Recruiting |
NCT00999791 -
Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
|
Phase 1 | |
| Completed |
NCT00886808 -
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
|
Phase 1 | |
| Recruiting |
NCT01218750 -
Triple Therapy for Diffuse Diabetic Macular Edema
|
N/A |